Galaxy Medicare
Close ·
Key Fundamentals
SMEHealthcare Equipment & SuppliesHealthcarePrice-based figures at the close · TTM
- ROCE
- 13.90%
- Debt to Equity
- 0.10
- EPS (TTM)
- —
- Book Value
- ₹22.83
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 0.78
- ROE
- 10.80%
- Dividend Yield
- 3.95%
- EBITDA
- ₹5.50 Cr
- 52W High
- ₹23.80
- 52W Low
- ₹15.15
Peer Comparison
Healthcare › Medical Equipment › Medical Equipment & Supplies
| ₹1,381.80 | 123.38 | ₹15,607 Cr | 11.63 | 0.00% | 13.80% | 18.00% | ₹1,077 Cr | ₹125 Cr | |
| ₹1,586.80 | 51.04 | ₹15,325 Cr | 5.18 | 0.23% | 9.02% | 12.50% | ₹1,997 Cr | ₹313 Cr | |
| ₹25.23 | 66.39 | ₹1,611 Cr | 3.61 | 0.20% | 8.91% | 11.40% | ₹367 Cr | ₹24 Cr | |
| ₹311.10 | 148.85 | ₹1,603 Cr | 2.61 | 0.67% | 2.44% | 4.59% | ₹441 Cr | ₹11 Cr | |
| ₹527.15 | 24.98 | ₹1,243 Cr | 2.52 | 0.00% | 26.00% | 22.40% | ₹201 Cr | ₹34 Cr | |
| ₹188.71 | 33.64 | ₹1,017 Cr | 4.27 | 0.00% | 14.80% | 15.00% | ₹287 Cr | ₹31 Cr | |
| ₹608.10 | — | ₹868 Cr | 5.64 | 0.00% | 16.90% | 18.90% | — | — | |
| Galaxy Medicare (this company) | ₹17.70 | — | ₹27 Cr | 0.78 | 3.95% | 10.80% | 13.90% | — | — |
| Median 8 companies | ₹419.13 | 58.72 | ₹1,423 Cr | 3.94 | 0.10% | 12.30% | 14.45% | ₹404 Cr | ₹33 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 81/100
Category scores
- Quality
- 50
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 77
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 40
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 61
- Good
- Solvency, leverage, coverage 9% weight
- Momentum
- 45
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 52
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Stock is trading at 0.63 times its book value
- Company has been maintaining a healthy dividend payout of 19.2%
Weaknesses
2- The company has delivered a poor sales growth of 6.84% over past five years.
- Company has a low return on equity of 13.5% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 7 | 2 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 48.60
- Neutral
- MACD (12,26,9)
- 0.09
- Bearish
- SMA (50)
- 17.68
- Bullish
- SMA (200)
- 18.76
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +6.84% |
|---|---|
| 3Y | +8.73% |
| 1Y | +2.34% |
Net profit
| 5Y | +36.56% |
|---|---|
| 3Y | +29.63% |
| 1Y | +1.48% |
Operating cash flow
| 5Y | −20.46% |
|---|---|
| 3Y | −21.44% |
| 1Y | −60.58% |
Operating margin· change in pp
| 5Y | +3.30 pp |
|---|---|
| 3Y | +3.26 pp |
| 1Y | −1.23 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2021 | ₹28.57 Cr |
|---|---|
| Mar 2023 | ₹30.94 Cr |
| Mar 2024 | ₹35.84 Cr |
| Mar 2025 | ₹38.86 Cr |
| Mar 2026 | ₹39.77 Cr |
Net profit by year
| Mar 2021 | ₹0.72 Cr |
|---|---|
| Mar 2023 | ₹1.57 Cr |
| Mar 2024 | ₹3.71 Cr |
| Mar 2025 | ₹3.37 Cr |
| Mar 2026 | ₹3.42 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 17.24 | 21.96 | 18.73 | 21.27 |
| Expenses | 14.74 | 19.81 | 15.87 | 19.9 |
| Operating Profit | 2.5 | 2.15 | 2.86 | 1.37 |
| OPM % | 14.5% | 9.79% | 15.27% | 6.44% |
| Other Income | 0.55 | 0.52 | 0.33 | 0.98 |
| Interest | 0.38 | 0.31 | 0.11 | 0.16 |
| Depreciation | 0.25 | 0.25 | 0.3 | 0.25 |
| PBT | 2.42 | 2.11 | 2.78 | 1.94 |
| Tax % | 29.34% | 21.8% | 27.34% | 27.32% |
| Net Profit | 1.71 | 1.66 | 2.02 | 1.4 |
| EPS (₹) | 1.44 | 1.4 | 1.33 | 0.92 |
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 28.57 | 30.94 | 35.84 | 38.86 | 39.77 |
| Expenses | 26.41 | 28.59 | 30.87 | 34.16 | 35.45 |
| Operating Profit | 2.16 | 2.35 | 4.97 | 4.7 | 4.32 |
| OPM % | 7.56% | 7.6% | 13.87% | 12.09% | 10.86% |
| Other Income | 0.5 | 1.72 | 1.18 | 1.07 | 1.22 |
| Interest | 0.8 | 0.95 | 0.94 | 0.74 | 0.28 |
| Depreciation | 0.82 | 1.12 | 0.48 | 0.5 | 0.55 |
| PBT | 1.04 | 2 | 4.73 | 4.53 | 4.71 |
| Tax % | 30.77% | 21.5% | 21.56% | 25.61% | 27.39% |
| Net Profit | 0.72 | 1.57 | 3.71 | 3.37 | 3.42 |
| EPS (₹) | 2.57 | 5.16 | 3.13 | 2.84 | 2.25 |
| Div. Payout % | 9.72% | 0% | 0% | 26.39% | 31.05% |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 2.8 | 3.04 | 11.86 | 11.86 | 15.17 |
| Reserves | 12.88 | 14.78 | 9.51 | 12.29 | 25.17 |
| Borrowings | 8.78 | 9.15 | 8.12 | 4.61 | 4.2 |
| Other Liabilities | 5.44 | 5.34 | 3.05 | 2.73 | 4.23 |
| Total Liabilities | 29.9 | 32.31 | 32.54 | 31.49 | 48.77 |
| Fixed Assets | 13.95 | 14.57 | 14.41 | 14.13 | 15.03 |
| CWIP | 0.2 | 0.06 | 0 | 0 | 0 |
| Investments | 2.98 | 2.69 | 3.11 | 2.82 | 2.87 |
| Other Assets | 12.77 | 14.99 | 15.02 | 14.54 | 30.87 |
| Total Assets | 29.9 | 32.31 | 32.54 | 31.49 | 48.77 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 5.56 | 3.65 | 2.71 | 4.49 | 1.77 |
| Investing | −4.46 | −1.91 | −0.65 | 0.32 | −13.9 |
| Financing | −1.11 | −1.8 | −2.08 | −4.72 | 12.09 |
| Net Cash Flow | 0 | −0.07 | −0.03 | 0.09 | −0.05 |
| Free Cash Flow | 1.09 | 2.9 | 2.5 | 4.37 | 0.21 |
| CFO/OP | 273 | 170 | 76 | 118 | 67 |
Ratios
| Particulars | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 93.26 | 107 | 74.65 | 64.72 | 69.93 |
| Inventory Days | 73.9 | 101 | 124 | 84.75 | 98.62 |
| Days Payable | 102 | 91.77 | 32.29 | 22.05 | 43.69 |
| Cash Conversion Cycle | 65.5 | 116 | 166 | 127 | 125 |
| Working Capital Days | 0.51 | 36.1 | 56.93 | 68.94 | 94.62 |
| ROCE % | — | — | 18.53% | 17.72% | 13.86% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Galaxy Medicare insights
55 extracted metrics across FY21–FY26.
Documents
- 29 Sep 2026
- 28 Sep 2026
- 25 Sep 2026
- 4 Sep 2026
Frequently Asked Questions about Galaxy Medicare
What does Galaxy Medicare Ltd do?
Where is Galaxy Medicare Ltd (GML) listed?
Which sector does Galaxy Medicare Ltd belong to?
What is the 52-week high and low of Galaxy Medicare Ltd?
Does Galaxy Medicare Ltd pay dividends?
What is the Return on Equity (ROE) of Galaxy Medicare Ltd?
Company Information
Incorporated in July 1992, Galaxy Medicare Limited manufactures and exports medical devices, POP bandages, and surgical dressings in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GML.md for Galaxy Medicare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.